Literature DB >> 12053175

A tumor-homing peptide with a targeting specificity related to lymphatic vessels.

Pirjo Laakkonen1, Kimmo Porkka, Jason A Hoffman, Erkki Ruoslahti.   

Abstract

Blood vessels of tumors carry specific markers that are usually angiogenesis-related. We previously used phage-displayed peptide libraries in vivo to identify peptides that home to tumors through the circulation and that specifically bind to the endothelia of tumor blood vessels. Here we devised a phage screening procedure that would favor tumor-homing to targets that are accessible to circulating phage, but are not blood vessels. Screening on MDA-MB-435 breast carcinoma xenografts yielded multiple copies of a phage that displays a cyclic 9-amino-acid peptide, LyP-1. Homing and binding to tumor-derived cell suspensions indicated that LyP-1 also recognizes an osteosarcoma xenograft, and spontaneous prostate and breast cancers in transgenic mice, but not two other tumor xenografts. Fluorescein-labeled LyP-1 peptide was detected in tumor structures that were positive for three lymphatic endothelial markers and negative for three blood vessel markers. LyP-1 accumulated in the nuclei of the putative lymphatic cells, and in the nuclei of tumor cells. These results suggest that tumor lymphatics carry specific markers and that it may be possible to specifically target therapies into tumor lymphatics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12053175     DOI: 10.1038/nm720

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  143 in total

1.  Gene delivery mediated by recombinant silk proteins containing cationic and cell binding motifs.

Authors:  Keiji Numata; Juliana Hamasaki; Balajikarthick Subramanian; David L Kaplan
Journal:  J Control Release       Date:  2010-05-10       Impact factor: 9.776

2.  Lymphatic microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of the literature.

Authors:  Jun Wang; Kainan Li; Baocheng Wang; Jingwang Bi
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

Review 3.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

Review 4.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

Review 5.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

6.  Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.

Authors:  Carlos M Galmarini; Galya Warren; Madapathage T Senanayake; Serguei V Vinogradov
Journal:  Int J Pharm       Date:  2010-05-24       Impact factor: 5.875

Review 7.  Preclinical lymphatic imaging.

Authors:  Fan Zhang; Gang Niu; Guangming Lu; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

Review 8.  Silk-based delivery systems of bioactive molecules.

Authors:  Keiji Numata; David L Kaplan
Journal:  Adv Drug Deliv Rev       Date:  2010-03-16       Impact factor: 15.470

9.  Nanocrystal targeting in vivo.

Authors:  Maria E Akerman; Warren C W Chan; Pirjo Laakkonen; Sangeeta N Bhatia; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

10.  Cooperative nanomaterial system to sensitize, target, and treat tumors.

Authors:  Ji-Ho Park; Geoffrey von Maltzahn; Mary Jue Xu; Valentina Fogal; Venkata Ramana Kotamraju; Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.